Prof. Armin Giese

Chief Scientific Officer at MODAG

Prof. Armin Giese's work experience includes their current position as Chief Scientific Officer at MODAG since June 2019. Prior to this, they held various roles at Ludwig-Maximilians Universität München from 2000 to 2019, including Professor of Neuropathology, Deputy Head and Acting Head of the Center for Neuropathology and Prion Research, and Acting Head of the German Reference Center for Neurodegenerative Diseases. Prof. Armin also worked as a Senior Physician and Resident Physician at the Center for Neuropathology and Prion Research and as a Resident Physician at the Institute of Neuropathology and the Department of Psychiatry. Before joining Ludwig-Maximilians Universität München, they were a Resident Physician at the Departments of Pathology and Neuropathology at Georg-August-Universität Göttingen from 1994 to 2000.

Prof. Armin Giese completed their education with a Bachelor of Science degree from UCL in 1992. Prof. Armin then pursued their Doctor of Medicine degree at Kiel University from 1987 to 1994. Following that, they earned their "Dr. med." from The University of Göttingen between 1994 and 1999. Finally, they obtained a Habilitation degree in Neuropathologie from Ludwig-Maximilians-Universität München, completing their studies in 2006.

Location

Wendelsheim, Germany

Links


Org chart


Teams

This person is not in any teams


Offices


MODAG

MODAG aims to provide a novel approach for treating neurodegenerative diseases by combining targeted small molecule therapeutics with the right diagnostic tools. Their first objective is to demonstrate clinical proof-of-concept with their lead compound anle138b in Multiple System Atrophy (MSA) seeking to halt the progression and provide a firstdisease-modifying therapeutic.This success will allow us to apply their technology to similar diseases such as Parkinson’s and other synucleinopathies with the goal of dissolving disease-related intra-cellular oligomers, thereby reducing their toxic properties.MODAG is comprised of experts in the clinical research and neurodegenerative disease space and supported by grants from leading patient organizations including the Michael J Fox Foundation, Cure Parkinson's Trust and Parkinson’s UK.


Employees

11-50

Links